Navigation Links
BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition
Date:12/5/2008

BIRMINGHAM, Ala., Dec. 5 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) announced today that the Company will present pre-clinical data on Forodesine HCl and BCX-4208, and clinical data on BCX-4208 at the 50th American Society of Hematology (ASH) Annual Meeting and Exposition being held in San Francisco, CA from December 6-9, 2008. Forodesine HCl and BCX-4208 are clinical-stage purine nucleoside phosphorylase (PNP) inhibitors.

The schedule for BioCryst's poster presentations at ASH is as follows:

BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor is a Novel, Potent Orally Active Anti T- and B-Cell Agent (Poster # 1547)

Saturday, December 6, 2008, 5:30 p.m. - 7:30 p.m. Pacific Time; Hall A

A Phase II Study of the Purine Nucleoside Phosphorylase (PNP) Inhibitor RO5092888 (BCX-4208) in Patients with Moderate to Severe Chronic Plaque Psoriasis: Safety, Tolerability and Lymphocyte Effects (Poster # 2583)

Sunday, December 7, 2008, 6:00 p.m. - 8:00 p.m. Pacific Time; Hall A

In-Vitro Efficacy of the Deoxyguanoside Analogs Forodesine (BCX-1777) and ARA-G in Pediatric Acute Lymphoblastic Leukemia Cells (Poster # 1925)

Sunday, December 7, 2008, 6:00 p.m. - 8:00 p.m. Pacific Time; Hall A

About BioCryst

BioCryst is an integrated biopharmaceutical company utilizing crystallography and structure-based drug design to develop a deep pipeline of novel therapeutics targeting major illnesses. BioCryst is currently advancing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma. In addition, the Company has a pre-clinical portfolio of novel compounds, directed against infectious, cardi
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
2. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
3. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
4. BioCryst to Present at the JMP Healthcare Focus Conference
5. BioCryst to Present at UBS 2008 Global Life Sciences Conference
6. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
7. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
8. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
9. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
10. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
11. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...30 BioMarin Pharmaceutic...Food and Drug Administration (FDA) has granted orp...DAP), amifampridine phosphate, for the rare autoim...MS). 3,4-DAP has previously received orphan drug ...e Committee for Medicinal Products for Human Use o...
(Date:11/30/2009)...GEN, Nov. 30 Exiqon A/S (NASDAQ OM...ard Medical School ICCB-Longwood Screening Facilit...ning Center of Excellence. ICCB-L supports invest...hospitals and institutions, for high-throughput sc..., MicroRNAs are a novel class of small, non-coding...
(Date:11/30/2009)..., AMSTERDAM, November 30 /PRNewswire-FirstC... scientific, medical and technical products and se...e, its comprehensive biomedical,database which hol...7,000,active, peer reviewed journals. , E...t of new biomedical,and pharmaceutical insights. N...
(Date:11/27/2009)...Nov. 27 Cromoz Inc., located in Re...carbon nanotube-based cancer drug delivery system ...tubes, which have functional groups on the walls t...developed in partnership with the Indian Institute...serves as a drug delivery vehicle with the ability...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2
...., Sept. 17 Diageo (NYSE: DEO ),the world,s lead...nounce,its sponsorship of a physician,s training p...ues developed by the Medical Society of the State ... by Diageo as an unrestricted grant, is,being deve...assess issues,related to alcohol abuse. This train...
...versity of the Year Announces Potential Breakthrou...titis C., CHICAGO, Sept. 17 The British Midlands...University of Nottingham in the,British Midlands h...of a,possible Hepatitis C Vaccine. The United Kin...tor,generating revenues in excess of $8.6 billion ...
...pt. 17 /PRNewswire-FirstCall/ - Angiotech Pharmace... today that it reached a favourable,agreement with...("Conor"),to settle all outstanding patent litigat...tent. "With this agreement now in place, Angiotec...d enforce our intellectual property should decreas...
Other Biology Technology:Diageo Sponsors Medical Society of the State of New York's Physicians Training Program 2Diageo Sponsors Medical Society of the State of New York's Physicians Training Program 3The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine 2The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine 3Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation 2Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation 3Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation 4
(Date:11/30/2009)...OUSTON (Nov. 30, 2009) Scientists and engineers f...ne and energy will come together Dec. 7 with lead...g oil and pumping blood. , Much like moving oil ...ugh the body. Both systems need clean, well-funct... or corrosion, to function efficiently. Both indus...
(Date:11/30/2009)...OBOKEN, N.J. - The inaugural Global Conference on... 3-4, 2009, in Washington, DC, focuses on the conv...ises of critical importance to society. , Th...f research activity around targeted complex system... year,s topic includes Critical Infrastructure Sys...
(Date:11/30/2009)...s global temperatures continue to rise scientists ...tanding how species respond and adapt. In a paper ...Dr Francisco Rodriguez-Trelles and Dr Miguel Rodri...global warming of approximately 0.6˚C has alr...challenge facing ecologists and evolutionary biolo...
Breaking Biology News(10 mins):Similarities of pumping blood and oil examined 2Similarities of pumping blood and oil examined 3First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4 2How can scientists measure evolutionary responses to climate change? 2Psoriasis Cure Now Welcomes Institute of Medicine Report Urging Comparative Effectiveness Research on Psoriasis But Worries About Risk of Rationing 50467 1Psoriasis Cure Now Welcomes Institute of Medicine Report Urging Comparative Effectiveness Research on Psoriasis But Worries About Risk of Rationing 50467 2Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 1Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 2Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 3Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 4Excalibur International Marine 2849 25 Owned by EFT BioTech Holdings 29 Completes Inaugural Passenger Crossing of Taiwan Strait 12858 1Excalibur International Marine 2849 25 Owned by EFT BioTech Holdings 29 Completes Inaugural Passenger Crossing of Taiwan Strait 12858 2Excalibur International Marine 2849 25 Owned by EFT BioTech Holdings 29 Completes Inaugural Passenger Crossing of Taiwan Strait 12858 3
...e than 25 years, stem cells have been defined base...well as multiple different specialized cell types....y powerful, many scientists have sought a more mol...s they express. , Now, a team of Canadian scienti...f a gene called Oct4 considered to be the master r...
...gix, Inc. (OTC Bulletin Board: NRGX) today announc...rnal The Lancet of positive results from the first...nd the first report of direct gene transfer into a...nerative disease. , The open label Phase 1 study,...s disease demonstrated both a lack of adverse even...
...esistance to a retrovirus that infected chimpanzee...ironically may be at least partially responsible f...oday. , These findings, reported by a team of rese...in the June 22 issue of Science, provide a better ...rough the study of an ancient virus called Pan tro...
Other Biology News:Study identifies 5 genetic themes key to keeping stem cells in a primitive, flexible state 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 3Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 4Ancient retrovirus sheds light on modern pandemic 2Ancient retrovirus sheds light on modern pandemic 3
Mouse Anti-Human Troponin I Monoclonal Antibody, Unconjugated, Clone 22B11 from Santa Cruz Biotechnology, Inc.
Immulon 4 HBX 1x12 Strip from Thermo Scientific
Nar I from Promega
...kinase (rEK) is a highly purified preparation of t...ine protease which recognizes the identical cleava...;) and has similar enzymatic activity. Novagen&'s ...eld the highest activity available, and is qualifi...
Biology Products: